Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.50 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343618 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP2A6ERN1KDM4EMEN1 | |
| SCHEMBL28952758 | 0.96 | ALDH1A1 (0.52) | ALDH1A1CYP2A6ERN1KDM4EMEN1 | |
| SCHEMBL28952320 | 0.96 | ALDH1A1 (0.52) | ALDH1A1CYP2A6ERN1KDM4EMEN1 | |
| SCHEMBL5783154 | 0.93 | ALDH1A1 (0.54) | ALDH1A1CYP2A6ERN1KDM4EMEN1 | |
| SCHEMBL11809502 | 0.90 | ERN1 (0.56) | ALDH1A1CYP2A6ERN1KDM4EMEN1 | |
| SCHEMBL977774 | 0.85 | CYP2A6 (0.54) | ALDH1A1CYP2A6KDM4EPTGS2RAB9A | |
| SCHEMBL5930710 | 0.81 | CYP2A6 (0.54) | ALDH1A1CYP2A6KDM4EMEN1MAPT | |
| SCHEMBL5930707 | 0.81 | CYP2A6 (0.54) | ALDH1A1CYP2A6KDM4EMEN1MAPT | |
| SCHEMBL9883838 | 0.80 | CYP2A6 (0.50) | ALDH1A1CYP2A6KDM4EPTGS2RAB9A | |
| SCHEMBL19182196 | 0.80 | CYP2A6 (0.50) | ALDH1A1CYP2A6KDM4EPTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322165-A | Near-infrared fluorescence probe imaging dynamic fluctuation of ferrous ions in hepatic fibrosis | 镇江百单医疗生物科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| EP-0116454-A2 | Enhanced luminescent or luminometric assay | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-08-22 | — | — | EP | claimed |
| US-20260132295-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR MANUFACTURING ARTICLE, AND ARTICLE | AGC Inc. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4519384-B1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4652155-A1 | AMYLOID TARGETING AGENTS | Amydis, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12478693-B2 | Compositions and methods for detection of traumatic brain injury | Amydis, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250282723-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| US-20250213732-A1 | PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS | AMYDIS INC (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120097938-A | Synthesis method of 6- (piperazine-1-yl) -2-naphthaldehyde | 上海泰坦科技股份有限公司 | 2025-06-06 | — | — | CN | disclosed |
| CN-119985995-A | Compositions and methods for detecting traumatic brain injury | 阿米达斯公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-1472208-A1 | NOVEL 3-ARYL-2,5-DIHYDROXY-1,4-BENZOQUINONE DERIVATIVES, THEIR PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2004-11-03 | — | — | EP | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003066561-A1 | NOVEL 3-ARYL-2,5-DIHYDROXY-1,4-BENZOQUINONE DERIVATIVES, THEIR PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-5760048-A | TREATMENT OF STROKE AND NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5554767-A | NERVOUS SYSTEM, CARDIOVASCULAR, AND BRAIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132295-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, METHOD FOR MANUFACTURING ARTICLE, AND ARTICLE | MSR1, SEM1, ASH2L | ALDH1A1 2834/4885CYP2A6 3611/4885ERN1 1555/4885 |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | ALDH1A1 2952/4885CYP2A6 1095/4885ERN1 3905/4885 |
| US-12478693-B2 | Compositions and methods for detection of traumatic brain injury | S100B, FABP7, CRYAB | ALDH1A1 4102/4885CYP2A6 4482/4885ERN1 3255/4885 |
| US-20250282723-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | CRYAA, IAPP, APP | ALDH1A1 4174/4885CYP2A6 4681/4885ERN1 2177/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ALDH1A1 409/4885CYP2A6 1049/4885ERN1 1934/4885 |
| US-20250213732-A1 | PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS | PYGB, PSEN2, PSEN1 | ALDH1A1 4527/4885CYP2A6 4539/4885ERN1 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.